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Abstract Many viral pathogens target innate sensing cascades and/or cellular transcription
factors to suppress antiviral immune responses. Here, we show that the accessory viral protein U
(Vpu) of HIV-1 exerts broad immunosuppressive effects by inhibiting activation of the transcription
factor NF-kB. Global transcriptional profiling of infected CD4 +T cells revealed that vpu-deficient
HIV-1 strains induce substantially stronger immune responses than the respective wild type viruses.
Gene set enrichment analyses and cytokine arrays showed that Vpu suppresses the expression of
NF-kB targets including interferons and restriction factors. Mutational analyses demonstrated that
this immunosuppressive activity of Vpu is independent of its ability to counteract the restriction
factor and innate sensor tetherin. However, Vpu-mediated inhibition of immune activation required
an arginine residue in the cytoplasmic domain that is critical for blocking NF-kB signaling
downstream of tetherin. In summary, our findings demonstrate that HIV-1 Vpu potently suppresses
NF-kB-elicited antiviral immune responses at the transcriptional level.
DOI: https://doi.org/10.7554/eLife.41930.001
Introduction
Efficient replication of human immunodeficiency virus (HIV) depends on its ability to counteract or
evade a variety of antiviral defense mechanisms. Both adaptive and innate immune responses exert
tremendous selection pressure on the virus and form an environment that is hostile to viral replica-
tion. Nevertheless, HIV replicates and spreads successfully in its human host, still infecting about 2
million individuals each year. The success of HIV-1 in part depends on four so-called accessory pro-
teins (Vif, Nef, Vpr, and Vpu). These viral proteins can be dispensable for viral replication in vitro, but
are essential for high viral loads and efficient spread in vivo since they antagonize a variety of innate
immune sensors and/or effectors. The host restriction factors APOBEC3G, tetherin, and SERINC5,
for example are counteracted by Vif, Vpu, and Nef, respectively (Chemudupati et al., 2019;
Sauter and Kirchhoff, 2018; Simon et al., 2015).
Accumulating evidence suggests that lentiviral accessory proteins not only target specific compo-
nents of the cellular immune response at the protein level, but exert broad inhibitory effects by sup-
pressing antiviral immune responses also at the transcriptional level (Faust et al., 2017; Sauter and
Kirchhoff, 2018). For example, Vif, Vpr, and Vpu have all been suggested to inhibit expression of
interferon-b (IFN-b) and potentially other antiviral genes by depleting the cellular transcription factor
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IRF-3 (Doehle et al., 2012; Okumura et al., 2008; Park et al., 2014). Vpu-mediated degradation of
IRF-3, however, has been challenged and the immunosuppressive activity of Vpu has been ascribed
to its ability to inhibit NF-kB activation instead (Hotter et al., 2013; Manganaro et al., 2015;
Sauter et al., 2015). NF-kB is expressed in almost all cell types and governs the expression of hun-
dreds of genes in response to infection. Well-described targets of NF-kB comprise pro-inflammatory
cytokines such as IL-6, CXCL10, or IFN-b, as well as antiviral restriction factors including IFIT1 or
ISG15 (Hiscott et al., 1989; Libermann and Baltimore, 1990; Ohmori and Hamilton, 1993;
Pfeffer et al., 2004). Nevertheless, NF-kB-mediated immune activation fails to prevent HIV-1 infec-
tion. On the contrary, NF-kB activation and subsequent cytokine release may even contribute to a
detrimental chronic hyper-activation of the immune system that drives disease progression in HIV-
infected individuals, even under effective antiretroviral therapy (Miedema et al., 2013). Further-
more, NF-kB binding sites are also present in the lentiviral long terminal repeat (LTR) promoter and
are essential for efficient HIV transcription and replication (Calman et al., 1988; Chan and Greene,
2012). Thus, a better understanding of how HIV-1 infection modulates NF-kB-dependent immune
activation will provide important insights into the pathogenesis of AIDS and might help improve cur-
rent therapeutic approaches.
Vpu has been shown to suppress NF-kB-dependent gene expression via two independent mecha-
nisms. First, Vpu of pandemic HIV-1 group M viruses counteracts tetherin, which not only inhibits
virion release, but also acts as an innate sensor activating canonical NF-kB signaling upon detection
of viral infection (Gala˜o et al., 2012; Sauter et al., 2013; Tokarev et al., 2013). Second, Vpu stabil-
izes IkB, the inhibitor of NF-kB, and prevents the nuclear translocation of NF-kB independently of
tetherin (Akari et al., 2001; Bour et al., 2001; Leulier et al., 2003; Sauter et al., 2015). However,
despite the key role of NF-kB in immune activation, the effects of Vpu and the relative contribution
of both mechanisms on global cellular gene expression and immune activation remained unclear.
Here, we performed RNA-Seq analyses of human CD4 +T cells infected with primary HIV-1 clones
containing intact, disrupted, or selectively mutated vpu genes. Transcription factor network analyses
revealed that Vpu preferentially suppresses the expression of NF-kB target genes involved in adap-
tive and innate immune responses, such as antigen processing, major histocompatibility complex I
eLife digest The Human Immunodeficiency Virus (or HIV for short) has infected more than 70
million people worldwide. Although effective therapies exist to prevent the replication of the virus
and the development to AIDS, there is no cure or vaccine, and the virus still spreads efficiently in
human populations, infecting about 1.8 million new people every year.
The unfortunate success of HIV can in part be explained by several viral proteins that trick our
immune system and enable the virus to persist at high levels in the human body. For example, an
HIV protein called viral protein U (Vpu) prevents infected cells from producing alarm signals such as
interferons, which usually help healthy, uninfected cells to defend themselves against viruses.
However, the extent to which Vpu interferes with interferons and other proteins involved in immune
responses has remained unclear.
To address this question, Langer, Hammer, Hopfensperger et al. compared how different variants
of HIV affect immune responses in human cells. The experiments showed that cells infected with HIV
variants lacking Vpu released larger amounts of interferons and other cellular proteins that are
involved in immune responses compared to HIV variants with Vpu. Further experiments showed that
Vpu works by inhibiting the activation of a protein called NF-kB, which usually switches on genes
that encode interferons and many other proteins involved in immune responses.
These findings demonstrate that Vpu has a broader impact on the human immune response than
previously thought. In order to multiply efficiently, HIV initially requires the NF-kB protein to be
active. Therefore, when NF-kB is inactive, HIV may adopt a dormant state that prevents current
antiviral drug treatments from eradicating the virus in the human body. In the future, developing
new drugs that can activate dormant HIV particles may therefore have the potential to help cure HIV
infections.
DOI: https://doi.org/10.7554/eLife.41930.002
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(MHC-I) presentation, type I IFN signaling or DNA/RNA sensing. Furthermore, Vpu suppressed
expression of cellular host restriction factors (e.g. IFIT1-3, ISG15) and reduced the expression and
release of IFNs and other pro-inflammatory cytokines (e.g. IL-6, CXCL10) from HIV-1 infected cells. In
contrast to previous findings, we found no evidence for Vpu-mediated inhibition of IRF3-driven gene
expression. Our results rather corroborate the hypothesis that Vpu suppresses antiviral gene expres-
sion by inhibiting the activation of NF-kB. Mutational analyses revealed that inhibition of NF-kB and
the immunosuppressive effects of Vpu depend on an arginine residue in its first cytoplasmic alpha-
helix, while its ability to counteract the host restriction factor and innate sensor tetherin is dispens-
able. In summary, our results provide new insights into the transcriptional regulation of antiviral
immune responses by HIV-1 and demonstrate that the viral protein U exerts broader immunosuppres-
sive effects than previously known.
Results
Generation of selective Vpu mutants
To determine the effects of Vpu-mediated tetherin counteraction and downstream inhibition of NF-kB
signaling on immune activation, we generated HIV-1 mutants selectively impaired in either of these
inhibitory activities (Figure 1A). We selected the three primary viral isolates CH293, CH077, and STCO1
since they are derived from the most prevalent HIV-1 subtypes B and C and represent different stages
of infection (transmitted/founder or chronic viruses), different tropisms (R5/X4- or R5-tropic), and differ-
ent risk factors (homo- or heterosexual) (Figure 1B and Figure 1—figure supplement 1A). In order to
abrogate IkB stabilization and NF-kB inhibition downstream of tetherin, a previously described cyto-
plasmic arginine residue within Vpu was mutated to lysine (R45K in subtype B, R50K in subtype C)
(Pickering et al., 2014; Sauter et al., 2015; Yamada et al., 2018). As expected, a luciferase-based
reporter assay showed that HIV-1 constructs lacking Vpu or expressing the R/K mutant Vpu induced sig-
nificantly higher levels of NF-kB activation than the respective wild type (wt) viruses (Figure 1C). These
effects were independent of tetherin since tetherin is not expressed in HEK293T cells used in this exper-
imental setup. Comparison with fully Vpu-deficient mutants (vpu stop) revealed that loss-of-function in
the R/K mutants was complete for CH293 and STCO1, but only partial for CH077. Immunofluorescence
microscopy showed that Vpu-mediated suppression of NF-kB activity was associated with reduced
nuclear translocation of p65 (Figure 1—figure supplement 1B). In agreement with published data
(Kmiec et al., 2016; Vigan and Neil, 2010), mutations in an alanine interface in the transmembrane
domain of Vpu (A15L/A19L in subtype B, A20L/A24L in subtype C) abrogated the ability of all three
viruses to decrease tetherin surface levels (Figure 1D and Figure 1—figure supplement 2A) and to
counteract tetherin-mediated restriction of virus release (Figure 1E and Figure 1—figure supplement
2B). However, the AA/LL mutations had no effect on tetherin-independent NF-kB activation
(Figure 1C). Vice versa, the R/K mutations had no significant effect on Vpu-mediated tetherin counter-
action (Figure 1D and E and Figure 1—figure supplement 2). In agreement with their selective pheno-
type, the AA/LL and R/K mutants were expressed as efficiently as wild type Vpu (Figure 1F). Thus, the
phenotypic properties of these viruses allowed us to examine the relative contribution of tetherin-
dependent and -independent inhibition of NF-kB activation to Vpu-mediated effects on cellular gene
expression and the induction of antiviral immune responses.
Modulation of CD4 +T cell RNA expression profiles by wild type HIV-1
infection
To determine the effects of Vpu on host gene expression in a broad and unbiased manner, we ana-
lyzed the transcriptome of primary CD4 +T cells infected with the wt and the vpu-mutated viruses
described above. Three days post-infection, RNA sequencing (RNA-Seq) was performed to enable
rapid and deep profiling of transcripts. The sequencing of infected cells from four healthy donors
(two women, two men) (Figure 2A and Figure 2—figure supplement 1A, Supplementary file 1)
yielded 24.6 to 51.9 million reads per sample and an average sequence coverage of 82.6% (Fig-
ure 2—figure supplement 1B). No sample outliers were detected based on principal component
analysis and considering Cook’s distance, which measures the influence on fitted coefficients for a
gene by a single sample (Figure 2—figure supplement 1C).
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Figure 1. Generation of Vpu mutants that fail to inhibit NF-kB activation or to counteract tetherin. (A) Vpu-mediated inhibition of NF-kB activation via
two independent mechanisms. Asterisks illustrate mutations in Vpu that were introduced to selectively abrogate tetherin counteraction (orange) or
inhibition of NF-kB activation downstream of tetherin (blue). (B) Wt and mutant HIV-1 clones used in this study. MSM, man having sex with men; WSM,
woman having sex with men. (C) Vpu-mediated inhibition of NF-kB activation. HEK293T cells were co-transfected with the indicated proviral constructs,
Figure 1 continued on next page
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Principal component analyses revealed four major clusters, with the donor background account-
ing for the highest variation in gene expression (Figure 2B). Within each donor, the identity of the
viral isolate (i.e. CH293, CH077, and STCO1) had more pronounced effects on the cellular transcrip-
tome than the vpu genotype (i.e. wt, vpu stop, R/K, AA/LL). A similar pattern was observed in a heat
map of sample-to-sample distances (Figure 2—figure supplement 1D). Differences between the
transcriptomes of wt CH293-, CH077- and STCO1-infected cells may reflect specific effects of these
viruses on host gene expression and/or stem from differences in overall infection rates. In agreement
with the latter hypothesis, higher infection rates (Figure 2—figure supplement 1E) resulted in a
higher number of differentially expressed genes. For example, HIV-1 CH077 (infecting 60–80% of all
CD4 +T cells) significantly modulated the expression of 4202 genes, while CH293 (infecting 20–40%
of the cells) resulted in only 1565 differentially expressed genes and STCO1 (infecting 30–60% of the
cells) had an intermediate phenotype (Figure 2—figure supplement 1F). Importantly, infectious viral
doses of the mutants were adjusted to the respective wt viruses for unbiased analysis of the effect of
specific Vpu functions on host gene expression (Figure 2—figure supplement 1E).
Combined analysis of all three viral isolates revealed that 3369 genes were differentially
expressed comparing wt to mock infected CD4 +T cells (1587 up- and 1782 down-regulated)
(Figure 2C). Gene set enrichment analyses (KEGG) demonstrated that HIV-1 suppresses pathways
involved in transcription, translation, cell division and energy metabolism (Figure 2D). In agreement
with previous analyses in infected T cell lines (Chang et al., 2011; Kleinman et al., 2014), ‘spliceo-
some’, ‘RNA transport’ and ‘ribosome biogenesis’ were among the most strongly inhibited path-
ways. In contrast, gene sets involved in (antiviral) immunity including ‘chemokine signaling’, ‘T cell
receptor signaling’ and ‘antigen processing and presentation’ were induced upon wt HIV-1 infection
(Figure 2D).
These results demonstrate that the three HIV-1 primary isolates CH077, CH293 and STCO1
induce distinct transcription profiles in primary CD4 +T cells that allow us to assess the role of Vpu in
immune activation.
Vpu suppresses NF-kB-dependent antiviral gene expression
To determine the contribution of Vpu to the effects of HIV-1 on host gene expression, we compared
the transcriptomes of mutant vs. wt infected cells. Upon complete loss of Vpu (vpu stop vs. wt), 92
genes were differentially expressed (54 up, 38 down) across the three HIV-1 clones and four donors
tested, while seven genes (six up, one down) were differentially expressed upon selective loss of
Vpu-mediated NF-kB inhibition (NF-kB-def. Vpu mutant vs. wt) (Figure 3A and Figure 3—figure
supplement 1A). Notably, all six genes that were upregulated upon introduction of the R/K muta-
tion (i.e. GNG4, NFKBIA, RGS1, NFE2L3, SDC4, NFKB2) were also induced upon complete loss of
Vpu. In comparison, abrogation of tetherin counteraction did not significantly affect the expression
of any of the genes analyzed (tetherin-def. Vpu mutant vs. wt) (Figure 3—figure supplement 1A).
Figure 1 continued
a firefly luciferase-based NF-kB reporter vector, a Gaussia luciferase construct for normalization, and an expression vector for a constitutively active
mutant of IKKb as NF-kB inducer. Two days post-transfection, luciferase activity was determined. Mean values of three to seven independent
experiments, each performed in triplicate ±SEM are shown (*p<0.05; **p<0.01; RM one-way ANOVA with Greenhouse-Geisser correction and Dunnett’s
multiple comparison test). (D) Vpu-mediated down-modulation of tetherin. Human PBMCs were infected with the indicated VSV-G pseudotyped HIV-1
strains. Three days post-infection, tetherin surface levels of p24 positive cells were determined by flow cytometry. Mean values of three to five
independent experiments ± SEM are shown (*p<0.05; **p<0.01; ***p<0.001; RM one-way ANOVA with Greenhouse-Geisser correction and Dunnett’s
multiple comparison test). (E) Vpu-mediated enhancement of infectious virus yield. HEK293T cells were co-transfected with the indicated proviral
constructs and increasing amounts of an expression plasmid for human tetherin. Two days post-transfection, infectious virus yield was determined by
infection of TZM-bl reporter cells. Mean values of three to four independent experiments ± SEM are shown. (F) Expression of Vpu. HEK293T cells were
transfected with the indicated proviral constructs. Two days post-transfection, cells were harvested and analyzed by Western Blotting.
DOI: https://doi.org/10.7554/eLife.41930.003
The following figure supplements are available for figure 1:
Figure supplement 1. Vpu alignment and Vpu-mediated inhibition of nuclear translocation of p65.
DOI: https://doi.org/10.7554/eLife.41930.004
Figure supplement 2. Vpu-mediated counteraction of tetherin.
DOI: https://doi.org/10.7554/eLife.41930.005
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Figure 2. RNA sequencing of CD4 +T cells infected with wt or vpu-mutated HIV-1. (A) Experimental setup. CD4 +T cells of four healthy donors were
infected with wt or vpu-mutated HIV-1. Three days post-infection, cells were harvested and RNA sequencing was performed. (B) Principal component
analysis demonstrating that samples are clustered by donor (A - D) and virus (CH077, CH293, STCO1) rather than the vpu genotype. (C) MA plot
providing a global view of differentially expressed genes between Vpu wt and mock infected samples (combined analysis of CH077, CH293, and
STCO1). Red dots represent significant genes with a q value < 0.1 after Benjamini-Hochberg correction. (D) KEGG pathways significantly down- or up-
regulated upon infection with HIV-1 wt (combined analysis of CH077, CH293, and STCO1) (* q < 0.1; ** q < 0.01; *** q < 0.001). HIV-1 suppresses
pathways involved in transcription/translation (red), cell division (orange) and energy metabolism (purple), but induces immune responses (yellow),
signaling cascades (green) and pathways involved in cell-to-cell interactions and motility (blue). Pathway analysis was performed using GAGE
(Luo et al., 2009).
DOI: https://doi.org/10.7554/eLife.41930.006
The following figure supplement is available for figure 2:
Figure supplement 1. Isolation, infection and RNA sequencing of CD4 +T cells.
DOI: https://doi.org/10.7554/eLife.41930.007
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Figure 3. Vpu suppresses the induction of NF-kB-dependent immune responses. (A) Volcano plots illustrating differentially expressed genes (red) in
vpu stop vs. wt (left panel) or NF-kB-def. Vpu mutant vs. wt (right panel) infected CD4 +T cells. (B) Pie charts illustrating the relative size of gene sets
that are targeted by a specific transcription factor. Genes whose expression is significantly increased or decreased upon loss of vpu were analyzed in
the left and right panel, respectively. NF-kB target gene sets are highlighted in pink. (C) Pie charts illustrating the percentage of ISGs among different
Figure 3 continued on next page
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This agrees with our result that the AA/LL mutants is still able to prevent NF-kB activation down-
stream of tetherin (Figure 1A).
To determine whether the 92 genes modulated by Vpu share a common regulatory mechanism,
we performed transcription factor network analyses based on the transcription factor target (TFT)
gene sets of the Molecular Signatures Database (MSigDB) (Xie et al., 2005). This unbiased approach
revealed that Vpu preferentially suppresses the expression of NF-kB target genes, with gene sets
regulated by other transcription factors (including IRFs) playing only a minor role (Figure 3B, left
panel). In contrast, genes upregulated by Vpu (Figure 3B, right panel) showed no enrichment of NF-
kB target genes. The latter observation also excludes a potential bias due to the high number of
NF-kB target genes in the human genome.
In total, several hundred genes can be upregulated upon NF-kB activation, either directly or indi-
rectly. Of the more than 26.000 cellular transcripts covered by our RNA-Seq approach, about 3% are
NF-kB inducible (Figure 3—figure supplement 1B). This percentage increases to 30% and 67% in
genes, whose expression is up-regulated upon complete loss of Vpu or selective loss of Vpu-medi-
ated NF-kB inhibition, respectively (Figure 3—figure supplement 1B and C). In contrast, we did not
find any of 34 previously identified IRF3 targets (Grandvaux et al., 2002) among the transcripts
decreased in the presence of Vpu (data not shown).
In agreement with a key role of NF-kB in antiviral immunity, IFN-stimulated genes were also
enriched among genes suppressed by Vpu (Figure 3C). Among them were signaling molecules such
as TRAF1, TRAF4, or IKKe, but also previously described Vpu targets including the NK cell activating
receptor ULBP2 and the chemokine receptor CCR7 (Figure 3—figure supplement 1D, see arrows)
(Galaski et al., 2016; Ramirez et al., 2014). GO and KEGG gene set enrichment analyses demon-
strated that Vpu preferentially inhibits the induction of pathways involved in innate and adaptive
immunity including ‘response to type I IFN’ and ‘antigen processing and MHC I presentation’
(Figure 3D, left panel). Intriguingly, ‘cytosolic DNA sensing’ and ‘RIG-I like receptors’ were not sig-
nificantly induced by wt HIV-1 infection, but markedly upregulated upon disruption of vpu
(Figures 2D and 3D left panel). A similar phenotype was observed upon selective abrogation of
Vpu-mediated NF-kB inhibition (Figure 3D, right panel), strongly suggesting that these immunosup-
pressive effects of Vpu depend on its ability to prevent NF-kB activation.
As several host restriction factors (e.g. IFIT1, ISG15, HERC5) are expressed in an NF-kB-depen-
dent manner (Kroismayr et al., 2004; Pfeffer et al., 2004), we defined two additional custom gene
sets: ‘NF-kB target genes’ (Supplementary file 2; http://bioinfo.lifl.fr/NF-KB/) and ‘Host restriction
factors’ (Supplementary file 3; Kluge et al., 2015). Again, both of them were significantly upregu-
lated upon loss of Vpu or Vpu-mediated NF-kB inhibition (Figure 3D, bottom). Analysis of individual
genes revealed that Vpu significantly reduced mRNA levels of the host restriction factors APO-
BEC3B, HERC5, IFIT1-3, IFITM3, ISG15, MxA, OAS1 and Viperin, as well as IFN-b (Figure 3E). In
summary, these findings demonstrate that HIV-1 Vpu exerts broad immune-suppressive activity in
infected primary CD4 +T cells.
Vpu suppresses pro-inflammatory cytokine production
We selected pro-inflammatory cytokines such as IFN-b, IL-6, CXCL10/IP-10 for validation of our
RNA-Seq results. These factors represent known NF-kB targets with key roles in anti-viral immunity
Figure 3 continued
gene sets. The analysis is based on a list of ISGs obtained through the interferome v2.1 database (Rusinova et al., 2013) (***p<0.001; *p<0.05; Fisher’s
exact test). (D) Top10 KEGG and GO pathways that are induced upon complete loss of Vpu (left panel) or selective loss of Vpu-mediated NF-kB
inhibition (right panel). Modulation of two custom-defined gene sets (i.e. Restriction factors and NF-kB target genes) is shown at the bottom. Pathways
involved in intrinsic, innate or adaptive immunity are highlighted in yellow. Pathway analysis was performed using GAGE (Luo et al., 2009) (* q < 0.1; **
q < 0.01; *** q < 0.001). (E) n-fold modulation of host restriction factor and IFN-b mRNA levels upon loss of Vpu. Mean values of four independent
infections ± SEM are shown. Statistical significance was determined using negative binomial generalized linear models as implemented in DESeq2
(Love et al., 2014) (* q < 0.1; ** q < 0.01; *** q < 0.001). The dotted line indicates the mean change of restriction factor expression upon loss of Vpu.
DOI: https://doi.org/10.7554/eLife.41930.008
The following figure supplement is available for figure 3:
Figure supplement 1. Modulation of NF-kB-dependent gene expression by Vpu.
DOI: https://doi.org/10.7554/eLife.41930.009
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(Libermann and Baltimore, 1990; Ohmori and Hamilton, 1993), disease progression of HIV-1
infected individuals (Hamlyn et al., 2014; Jiao et al., 2012; Noel et al., 2014), and/or reactivation
of latent viral reservoirs (Hoshino et al., 2010). Quantitative RT-PCR confirmed that lack of Vpu-
dependent inhibition of NF-kB activation was associated with 2- to 11-fold increased IFN-b mRNA
expression levels in HIV-1 infected CD4 +T cells (Figure 4A, top panels). In case of HIV-1 CH077, the
R45K mutation had only modest effects, which is in agreement with its incomplete loss of NF-kB inhi-
bition (Figure 1C). Overall, the effects of the viruses on IFN-b induction correlated well with their
modulation of NF-kB activity (Figure 4A, bottom panels). Importantly, differences in IFN-b expres-
sion were not a consequence of different infection rates (Figure 4—figure supplement 1A).
To validate our RNA-Seq results at the protein level, we used a flow-cytometry-based approach
to quantify cytokine concentrations in the culture supernatants of CD4 +T cells at day three post-
infection. We selected STCO1 for our analyses as this strain results in high infection rates in CD4 +T
cells and shows a complete loss of NF-kB inhibition upon mutation of R45K. As before, virus stocks
were normalized for wt and mutant viruses (Figure 4—figure supplement 1B). The AA/LL mutations
abrogating tetherin counteraction had no marked effect on CXCL10 or IL-6 production. In contrast,
loss of Vpu-mediated NF-kB inhibition increased expression of these pro-inflammatory cytokines by
50% to 300% (Figure 4B). This result was confirmed in a membrane array-based approach that
allows simultaneous detection of 80 different cytokines. In addition to CXCL10 and IL-6, Vpu sup-
pressed the production of MIP-1b/CCL4, RANTES/CCL5, TNF-a/-b, IFN-g and many additional cyto-
kines in an NF-kB-dependent manner (Figure 4C). On average, complete lack of Vpu resulted in
32% and the single R45K mutation in 24% increases of NF-kB-inducible cytokine levels, respectively.
Thus, qRT-PCR and protein arrays confirmed the RNA-Seq results, demonstrating that Vpu sup-
presses pro-inflammatory cytokine expression via its ability to inhibit NF-kB activation.
Discussion
Besides its ability to decrease CD4 protein levels at the cell surface and to counteract tetherin, accu-
mulating evidence suggested that HIV-1 Vpu exerts much broader immunosuppressive effects by
inhibiting the activation of cellular transcription factors (Sauter and Kirchhoff, 2018). In the present
study, we therefore elucidated (1) the global impact of Vpu on host gene expression, (2) the tran-
scription factors that are targeted by Vpu, and (3) the role of tetherin counteraction in the immuno-
suppressive activity of Vpu. Combining the generation of selective vpu mutants of primary HIV-1
clones with a broad and unbiased RNA sequencing approach of infected CD4 +T cells, we show that
Vpu suppresses the transcription of a plethora of NF-kB-inducible host genes with key roles in intrin-
sic, innate and adaptive immune responses. qPCR analyses and quantification of cytokine release by
two independent methods confirmed that Vpu reduces the expression of type I IFNs and other pro-
inflammatory cytokines (Figure 4).
Since immune-modulatory functions are frequently impaired in lab-adapted HIV-1 strains
(Apps et al., 2016; Pickering et al., 2014), we exclusively used clones representing primary HIV-1
isolates, including one transmitted/founder virus. The latter establish successful infection upon trans-
mission and are characterized by an increased resistance to type I IFNs that enables efficient replica-
tion in an environment of augmented immune activation observed during acute infection (Iyer et al.,
2017; Parrish et al., 2013).
Selective abrogation of tetherin antagonism did not significantly change host gene expression,
demonstrating that tetherin-independent inhibition of NF-kB activation is sufficient for the immuno-
suppressive activity of Vpu. In agreement with this, a single arginine-to-lysine mutation abrogating
the ability of Vpu to inhibit NF-kB activation downstream of tetherin also resulted in significantly
increased expression of NF-kB target genes and the induction of various immunity pathways. Never-
theless, introduction of the R/K mutation had much less pronounced effects on host gene expression
than complete disruption of Vpu (Figure 3—figure supplement 1A,C,D). These differences may be
explained by NF-kB-independent effects of Vpu on transcription and/or result from an only partial
loss of NF-kB inhibition in the R/K mutants (Figure 1C).
The exact pathways triggering NF-kB activation in HIV-1 infected CD4 +T cells remain to be
determined. Although a number of innate HIV sensors (e.g. IFI16, cGAS, PQBP1) have been shown
to efficiently induce the activation of IRF3 and/or IRF7 (Jakobsen et al., 2013; Krapp et al., 2018;
Yoh et al., 2015), their relative contribution to NF-kB activation is still unclear. Besides pattern
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Figure 4. Vpu suppresses pro-inflammatory cytokine production. (A) Vpu inhibits IFN-b expression. CD4 +T cells were infected with the indicated
VSV-G pseudotyped HIV-1 strains. Three days post-infection, IFN-b mRNA levels were quantified by qRT-PCR and normalized to the respective mock
control. In the top panels, mean values of three to four independent experiments ± SEM are shown. The bottom panels show correlation analyses of
IFN-b mRNA levels and NF-kB activity (determined in Figure 1C) (*p<0.05; RM one-way ANOVA with Greenhouse-Geisser correction and Dunnett’s
multiple comparison test). (B) Vpu suppresses release of CXCL10 and IL-6. CD4 +T cells were infected with the indicated VSV-G pseudotyped HIV-1
STCO1 mutants. Three days post-infection, cytokine concentrations in the cell culture supernatant were quantified by flow cytometry using a bead-
based immunoassay, in which the analytes are captured between two antibodies. In the top panels, each data point represents results obtained with
one of three donors, normalized to the wild type control (100%). Error bars indicate SEM. Representative primary data of one donor are shown in the
bottom panels. Numbers indicate mean fluorescence intensity. (C) Vpu exerts broad suppressive effects on cytokine release. CD4 +T cells were infected
with the indicated VSV-G pseudotyped HIV-1 STCO1 mutants. Three days post-infection, cytokine release was determined using a cytokine array, based
on antibody-coated membranes. The heat map on the left illustrates relative cytokine release and is based on the mean of three independent
experiments. Cytokines that were not detectable in more than one donor were omitted from the heat map. Known NF-kB inducible genes (70) are
shown in pink. Arrows indicate CXCL10 and IL-6 that were also analyzed in panel (B). Mean changes ± SEM in cytokine release relative to HIV-1 wt are
shown in the right panel. (**p<0.01; ***p<0.001; RM one-way ANOVA with Greenhouse-Geisser correction and Dunnett’s multiple comparison test).
DOI: https://doi.org/10.7554/eLife.41930.010
The following figure supplement is available for figure 4:
Figure supplement 1. Infection rates of CD4 +T cells.
DOI: https://doi.org/10.7554/eLife.41930.011
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recognition receptors, activation via the T cell receptor complex may be an important determinant
of NF-kB activation (Jamieson et al., 1991). While our unbiased approach supports the hypothesis
that Vpu preferentially targets NF-kB-driven gene expression, it does not confirm previous studies
suggesting that Vpu suppresses the expression of IRF-3 target genes (Doehle et al., 2012;
Park et al., 2014). Interestingly, however, some of the genes targeted by Vpu share a regulation by
IRF-1, IRF-2 and/or IRF-8/ICSBP (Figure 3B). These transcription factors are IFN-g-inducible and may
cooperate with each other to prevent prolonged expression of IFN-stimulated genes (Elser et al.,
2002; Horiuchi et al., 2011; Kuwata et al., 2002; Tamura et al., 2005). However, the observed
effect of Vpu on IRF-1,–2 and  8 and their target genes may only be indirect since Vpu reduced the
release of IFN-g , an NF-kB target gene, from infected cells (Figure 4C).
Besides IFN-g , Vpu also suppressed the production of other cytokines, including IFN-b, CXCL10/
IP-10, IL-6 and TNF-a (Figure 4), even in the context of PHA-prestimulated CD4 +T cells. All these
factors are part of the cytokine storm during acute lentiviral infection (Abel et al., 2005;
Huang et al., 2016; Stacey et al., 2009), but fail to eliminate the virus. These pro-inflammatory
cytokines may even contribute to disease progression and accelerate pathogenesis of AIDS by
inducing prolonged hyper-activation of the immune system. For example, increased plasma levels of
CXCL10, TNF-a and IL-6 are associated with accelerated loss of CD4 +T cells in HIV-1 infected indi-
viduals (Borges et al., 2015; Liovat et al., 2012; Vaidya et al., 2014). During primary HIV-1 infec-
tion, CXCL10 plasma levels predict disease progression even better than plasma viral loads or
CD4 +T cell counts (Liovat et al., 2012). By modulating cellular cytokine production, Vpu may there-
fore be an important determinant of HIV-1 pathogenesis. Notably, however, the suppression of
immune activation by Vpu is incomplete, and wt HIV-1 still triggers the activation of a variety of
immune signaling pathways, including T cell, B cell, Fc and Toll-like receptor signaling (Figure 2D).
In fact, ‘RIG-I-like receptors’ and ‘cytosolic DNA sensing’ were the only immunity-related KEGG
pathways that were not significantly upregulated upon wt HIV-1 infection (Figure 2D). Thus, incom-
plete suppression of NF-kB activation and/or the induction of pathways involving transcription fac-
tors that are not directly targeted by Vpu may underlie the detrimental immune activation that
drives disease progression in HIV-1 infected individuals.
We also found that several host restriction factors (i.e. APOBEC3B, HERC5, IFIT1-3, IFITM3,
ISG15, MxA, OAS1 and Viperin) are significantly upregulated upon loss of Vpu (Figure 3E). The pro-
moters of many restriction factors contain both NF-kB- and IRF-responsive elements (Pfeffer et al.,
2004). Thus, this increase may either be a direct consequence of missing Vpu-mediated NF-kB inhi-
bition and/or the result of elevated cytokine levels. Our data suggest that HIV-1 uses Vpu to evade
certain restriction factors by counteracting them at the transcriptional level. In agreement with this,
we have previously shown that Vpu not only targets tetherin at the protein level, but also reduces its
mRNA expression (Sauter et al., 2015). Although many restriction factors are constitutively
expressed, their expression and hence antiviral effect usually increases upon infection and/or IFN
simulation. Thus, Vpu-mediated suppression of transcription may considerably relieve restriction. In
this regard, it is interesting to note, that no direct HIV-1 antagonist has been identified for most
restriction factors suppressed by Vpu (e.g. IFITs, HERC5, ISG15).
Among the differentially expressed genes, we also found several host factors previously
described as targets of Vpu (Figure 3—figure supplement 1D). For example, flow cytometric analy-
ses of HIV-1 wt- and Dvpu-infected cells demonstrated that Vpu decreases cell surface levels of the
NK cell activating ligands ULBP2/5/6 (Galaski et al., 2016) and the chemokine receptor CCR7
(Ramirez et al., 2014). Our RNA sequencing results suggest that Vpu does not (or at least not exclu-
sively) target these factors at the protein level but also prevents their expression by inhibiting the
activation of NF-kB.
Our results clearly demonstrate a broad immunosuppressive activity of Vpu in ex vivo infected pri-
mary CD4 +T cells. Furthermore, they are in agreement with the model that HIV-1 Nef boosts NF-kB
activation during early stages of infection to initiate efficient transcription of viral genes, while Vpu
suppresses NF-kB activation during later stages to limit antiviral gene expression of the host
(Sauter et al., 2015). However, the importance of this Vpu activity for viral replication, immune acti-
vation and disease progression during different stages of infection remains to be determined in vivo.
One limitation of the present study is the use of VSV-G for pseudotyping, which may influence sens-
ing and overall gene expression. Furthermore, the use of unsorted cells does not allow to discrimi-
nate between effects in infected and uninfected cells and may introduce a bias with respect to
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infection rates. Nevertheless, this potential confounder does not affect the comparison of wild type
and vpu mutated viruses as the variants of each strain were normalized for their infectivity to obtain
similar infection rates (Figure 2—figure supplement 1E). In fact, the present approach may even
underestimate the inhibitory effects of Vpu due to the presence of 25–80% uninfected bystander
cells and the pre-activation of CD4 +T cells with PHA.
It also remains to be clarified whether the inhibition of NF-kB activation by Vpu may compensate
for the loss of Nef-mediated down-modulation of the T cell receptor CD3 in HIV-1 and its direct sim-
ian precursors. The selective Vpu mutants generated in this study provide a valuable means to
address these questions in various in vivo models, including humanized mice (Yamada et al., 2015)
and a recently established monkey model (Joas et al., 2018). An important role of Vpu-mediated
NF-kB inhibition for efficient viral spread and replication in vivo is supported by the observation that
this activity is highly conserved among HIV-1 and closely related simian immunodeficiency viruses
(SIV) (Sauter et al., 2015). In contrast, HIV-2 and the majority of SIV species, which do not encode
Vpu, have evolved alternative mechanisms and prevent the activation of NF-kB via their accessory
proteins Nef or Vpr (Hotter et al., 2017). In fact, components of the canonical NF-kB signaling cas-
cade are targeted by diverse virus families. Well-described examples are IkB-like proteins encoded
by polydnaviruses (Falabella et al., 2007), the Vaccinia virus K1 protein, which prevents the acetyla-
tion of RelA (Bravo Cruz and Shisler, 2016) or African swine fever virus A238L, which binds p65/NF-
kB to prevent its nuclear translocation (Revilla et al., 1998). These examples of convergent viral evo-
lution highlight the importance of NF-kB in the antiviral immune response and demonstrate that
Vpu-mediated NF-kB inhibition is one of several sophisticated mechanisms that viruses have evolved
to prevent the manifold immune responses triggered by this transcription factor.
Materials and methods
Key resources table
Reagent type
(species)
or resource Designation Source or reference Identifiers Additional information
Gene (H. sapiens) Custom-defined gene
set of NF-kB target
genes
see
Supplementary file 2
of this paper
N/A
Gene (H. sapiens) Custom-defined
gene set
of host restriction
factors
see
Supplementary file 3
of this paper
N/A
Strain, strain
background (E. coli)
XL-2 blue Stratagene Cat#200150
Strain, strain
background
(E. coli)
XL2-Blue MRF’ TM
Ultracompetent cells
Agilent Technologies Cat#200151
Cell line
(H. sapiens)
HEK293T, female ATCC Cat#CRL-3216;
RRID: CVCL_0063
Cell line
(H. sapiens)
TZM-bl, female NIH Cat#8129;
RRID: CVCL_B478
Biological
sample
(H. sapiens)
peripheral blood
mononuclear
cells (donors A
and C: male;
donors B and
D: female)
DRK-Blutspendedienst
Baden-
Wu¨rttemberg-Hessen,
Ulm, Germany
N/A derived from four
healthy donors
Antibody anti-HIV-1 p24 (capsid
protein), FITC-conjugated
(mouse monoclonal)
Beckman Coulter Cat#6604665;
RRID: AB_1575987
FACS (1:25)
Antibody anti-BST-2/tetherin,
APC-conjugated
(mouse monoclonal)
Biolegend Cat#348410;
RRID:AB_2067121
FACS (1:20)
Continued on next page
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Continued
Reagent type
(species)
or resource Designation Source or reference Identifiers Additional information
Antibody anti-Human CD4,
PerCP-conjugated
(mouse monoclonal)
BD Pharmingen Cat#550631;
RRID:AB_393791
FACS (1:12.5)
Antibody anti-CD11c [3.9],
FITC-conjugated
(mouse monoclonal)
Abcam Cat#ab82445-100;
RRID:AB_1859733
FACS (1:12.5)
Antibody anti-CD11c [BU15],
FITC-conjugated
(mouse monoclonal)
Abcam Cat#ab22540 FACS (1:5)
Antibody IgG1, k, APC-
conjugated (mouse)
Biolegend Cat#400122;
RRID:AB_326443
FACS (1:20)
Antibody HIV-1 subtype C serum NIH Cat#11942 WB (1:5000)
Antibody HIV-1 NL4-3 Vpu
antiserum
N/A N/A WB (1:500);
kindly provided
by S. Bolduan
Antibody Anti-HIV1 p24
antibody [39/5.4A]
Abcam Cat#ab9071;
RRID:AB_306981
WB (1:5000)
Antibody Purified anti-GAPDH
antibody
Biolegend Cat#607902;
RRID:AB_2734503
WB (1:1000)
Antibody IRDye 800CW Goat
anti-Mouse
IgG (H + L)
LI-COR Cat#926–32210;
RRID:AB_621842
WB (1:20000)
Antibody IRDye 680RD
Goat anti-Rabbit
IgG (H + L)
LI-COR Cat#925–68071;
RRID:AB_2721181
WB (1:20000)
Antibody IRDye 800CW
Goat anti-Rat
IgG (H + L)
LI-COR Cat#925–32219;
RRID:AB_2721932
WB (1:20000)
Antibody anti-HIV-1 p24
(mouse monoclonal)
Abcam Cat#ab9071;
RRID:AB_306981
IF (1:500)
Antibody anti-p65
(rabbit polyclonal IgG)
Santa Cruz Cat#sc-372;
RRID:AB_632037
IF (1:150)
Antibody Donkey anti-Mouse
IgG (H + L), AF647-
conjugated
Thermo Scientific Cat#A31571;
RRID:AB_162542
IF (1:350)
Antibody Goat anti-Rabbit
IgG (H + L), AF568-
conjugated
Thermo Scientific Cat#A11011;
RRID:AB_143157
IF (1:350)
Recombinant
DNA reagent
pBR322_HIV-1
M subtype
B STCO1 wt (plasmid)
PMID: 23542380 N/A kindly provided
by B. Hahn
Recombinant
DNA reagent
pBR322_HIV-1 M
subtype B STCO1 vpu
stop (plasmid)
PMID: 27531907 N/A
Recombinant
DNA reagent
pBR322_HIV-1 M
subtype B STCO1 Vpu
R45K (plasmid)
PMID: 29324226 N/A
Recombinant
DNA reagent
pBR322_HIV-1 M
subtype B STCO1 Vpu
A15L/A19L (plasmid)
PMID: 27531907 N/A
Recombinant
DNA reagent
pUC57rev_HIV-1 M
subtype C CH293 w8
wt (plasmid)
PMID: 23542380 N/A kindly provided by B. Hahn
Continued on next page
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Reagent type
(species)
or resource Designation Source or reference Identifiers Additional information
Recombinant
DNA reagent
pUC57rev_HIV-1 M
subtype C CH293 w8
vpu stop (plasmid)
PMID: 2562070 N/A
Recombinant
DNA reagent
pUC57rev_HIV-1 M
subtype C CH293
w8 Vpu
R50K (plasmid)
this paper N/A derived from pUC57
rev_HIV-1 M subtype C
CH293 w8 wt (plasmid)
Recombinant
DNA reagent
pUC57rev_HIV-1
M subtype
C CH293 w8 Vpu A20L
/A24L (plasmid)
this paper N/A derived from pUC57
rev_HIV-1 M subtype C
CH293 w8 wt (plasmid)
Recombinant
DNA reagent
pCR-XL-TOPO_HIV-1 M subtype
B CH077 wt
(plasmid)
PMID: 22190722 N/A kindly provided by B. Hahn
Recombinant
DNA reagent
pCR-XL-TOPO_HIV-1 M subtype
B CH077
vpu stop
(plasmid)
PMID: 27531907 N/A
Recombinant
DNA reagent
pCR-XL-TOPO_HIV-1 M subtype
B CH077
Vpu R45K
(plasmid)
this paper N/A derived from pCR-XL-
TOPO_HIV-1 M subtype
B CH077 wt (plasmid)
Recombinant
DNA reagent
pCR-XL-TOPO_HIV-1 M subtype
B CH077
Vpu A15L/A19L
(plasmid)
PMID: 27531907 N/A
Recombinant
DNA reagent
p_human IKKb,
constitutively
active mutant (S177E,
S181E) (plasmid)
PMID: 23552418 N/A kindly provided by
B. Baumann
Recombinant
DNA reagent
p_NF-kB(3x)-Firefly
Luciferase (plasmid)
PMID: 23552418 N/A kindly provided by
B. Baumann
Recombinant
DNA reagent
pTAL_Gaussia Luciferase (plasmid) PMID: 23552418 N/A
Recombinant
DNA reagent
pCG_human Tetherin
IRES DsRed2 (plasmid)
PMID: 19917496 N/A
Recombinant
DNA reagent
pHIT-G_VSV-G (vesicular
stomatitis virus
glycoprotein) (plasmid)
PMID: 9303297 N/A
Sequence-
based reagent
Primers used for
mutagenesis of vpu
see
Supplementary file 4
of this paper
N/A
Sequence-
based reagent
TaqMan Gene
Expression
Assay for IFN-beta
Thermo Fisher
Scientific
Cat#Hs01077958_s1
Sequence-
based reagent
Human GAPD (GAPDH)
Endogenous Control
(VIC/TAMRA probe,
primer limited)
Thermo Fisher
Scientific
Cat#4310884E
Peptide,
recombinant
protein
IRDye 800CW
streptavidin, 0.5 mg
LI-COR Cat#926–32230
Commercial
assay or kit
GalScreen Applied Bioscience Cat#T1027
Commercial
assay or kit
PrimeScript
RT-PCR Kit
TAKARA Cat#RR014A
Continued on next page
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Continued
Reagent type
(species)
or resource Designation Source or reference Identifiers Additional information
Commercial
assay or kit
RNeasy Plus
Mini kit
QIAGEN Cat#74136
Commercial
assay or kit
RosetteSep
Human
CD4 + T Cell
Enrichment
Cocktail
Stem Cell
Technologies
Cat#15062
Commercial
assay or kit
Luciferase Assay
System 10-pack
Promega Cat#E1501
Commercial
assay or kit
LEGENDplex Human
Anti-Virus Response
Panel
BioLegend Cat#740390
Commercial
assay or kit
RayBio C-Series
Human
Cytokine Antibody
Array C5
RayBiotech Cat#AAH-CYT-5–8
Commercial
assay or kit
FIX and PERM Kit
(CE-IVD) (1000 Tests)
Nordic-MUbio Cat#GAS-002–1
Commercial
assay or kit
DNA-free
DNA Removal Kit
ThermoFisher
Scientific
Cat#AM1906
Commercial
assay or kit
QuikChange II XL Site-
Directed Mutagenesis
Kit
Agilent Cat#200522
Commercial
assay or kit
TruSeq Stranded
mRNA Sample Prep Kit
illumina Cat#RS-122–2101
Commercial
assay or kit
Thermo Script
RT-PCR system
Invitrogen Cat#11146–016
Commercial
assay or kit
Signal Enhancer
HIKARI
kit for Western
Blotting and ELISA
Nacalai Tesque Cat#02267–41
Chemical
compound, drug
Human IL-2 IS,
premium grade
MACS Miltenyi
Biotec
Cat#130-097-745
Chemical
compound, drug
Remel PHA purified ThermoFisher
Scientific
Cat#R30852801
Chemical
compound, drug
Recombinant
human TNFa
Sigma Aldrich Cat#H8916-10UG
Chemical
compound, drug
DAPI Sigma Aldrich Cat#D9542-1MG
Software,
algorithm
BD FACSDiva
Version 8.0
BD Biosciences https://www.
bdbiosciences.
com;
RRID: SCR_001456
Software,
algorithm
Corel DRAW 2017 Corel Corporation https://www.
coreldraw.com/
Software,
algorithm
GraphPad Prism
Version 5.03
GraphPad Software, Inc. https://www.
graphpad.com;
RRID: SCR_002798
Software,
algorithm
ImageJ Open source http://imagej.
nih.gov/ij/
Software,
algorithm
LI-COR Image Studio
Lite Version 3.1
LI-COR www.licor.com/;
RRID: SCR_013715
Software,
algorithm
FlowJo_V10 Tree Star, Inc. https://www.flowjo.com
Continued on next page
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Continued
Reagent type
(species)
or resource Designation Source or reference Identifiers Additional information
Software,
algorithm
ZEN Zeiss https://www.zeiss.com/
microscopy/int/products
/microscope
-software/zen.html;
RRID:SCR_013672
Software,
algorithm
Fiji Open source
(Max Planck
Institute of Molecular
Cell Biology and
genetics,
Dresden, Germany)
https://imagej.net/Fiji;
RRID:SCR_002285
Software,
algorithm
GeneMANIA Open source http://genemania.org/
Software,
algorithm
Heatmapper Open source http://www2.
heatmapper.ca/
expression/
Software,
algorithm
R Open source https://www.
r-project.org/
Software,
algorithm
Kallisto PMID: 27043002 https://pachterlab.
github.io/kallisto/
Software,
algorithm
DESeq2 PMID: 25516281 https://
bioconductor.org/
packages/
release/bioc
/html/DESeq2.html
Software,
algorithm
GAGE PMID: 19473525 https://bioconductor.
org/
packages/release/bioc/
html/gage.html
Software,
algorithm
StepOne and Step
OnePlus Software
v2.3
Thermo Fisher
Scientific
https://www.
thermofisher
.com/de/de/
home/technical
-resources/software
-downloads/StepOne-
and-StepOnePlus-Real-
Time-PCR-
System.html
Other Rel/NF-kB target
gene database
Open source http://bioinfo.
lifl.fr/NF-KB/
Other RNAseq Data this paper GEO accession
GSE117655
Other Interferome
database
PMID: 23203888 http://www.
interferome.
org/interferome
/home.jspx
Cell culture
Human embryonic kidney 293T (HEK293T, RRID: CVCL_0063), obtained from the American Type
Culture Collection (ATCC), was first described by DuBridge and colleagues (DuBridge et al., 1987).
TZM-bl cells (RRID: CVCL_B478) are a HeLa-derived reporter cell line and were obtained through
the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH, from John C Kappes, Xiaoyun Wu,
and Tranzyme, Inc (Platt et al., 1998). HEK293T and TZM-bl cells were authenticated by the ATCC
and NIH, respectively and maintained in Dulbecco’s modified Eagle medium (DMEM) supplemented
with 10% FCS, 2 mM glutamine, streptomycin (100 mg/ml), penicillin (100 U/ml). Both cell lines were
tested for mycoplasma contamination every three months. Only mycoplasma negative cells were
used for this study.
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PBMCs were isolated using lymphocyte separation medium (Biocoll separating solution; Bio-
chrom, Berlin, Germany). CD4 +T cells were isolated using the RosetteSep Human CD4 +T Cell
Enrichment Cocktail (Stem Cell Technologies, Vancouver, Canada). Primary cells were cultured in
RPMI-1640 containing 10% fetal calf serum (FCS), 2 mM glutamine, streptomycin (100 mg/ml), peni-
cillin (100 U/ml), and 66 IU/ml = 10 ng/ml interleukin 2 (IL-2). Before infection, primary cells were
stimulated for three days with phytohemagglutinin (PHA) (1 mg/ml). The use of human PBMCs was
approved by the Ethics Committee of the Ulm University Medical Center. All donors were anony-
mized and provided informed written consent.
Proviral constructs and mutagenesis
Infectious molecular clones of HIV-1 CH293, CH077 and STCO1 were kindly provided by Beatrice H.
Hahn (Ochsenbauer et al., 2012; Parrish et al., 2013). Vpu stop mutations were introduced using
the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent, Santa Clara, CA); all other vpu muta-
tions were introduced using SOE-PCR-based mutagenesis (see Supplementary file 4 for primers).
Generation of virus stocks
HEK293T cells were co-transfected in a 6-well format with proviral constructs (5 mg) and an expres-
sion plasmid for the vesicular stomatitis virus glycoprotein (pHIT_VSV-G; 1 mg) (Fouchier et al.,
1997) using the calcium phosphate method. Two days post-transfection, cell culture supernatants
were harvested and cleared by centrifugation (1700 g, 4 min, 4˚C, Centrifuge 5417C (Eppendorf,
Hamburg, Germany), fixed-angle rotor F-45-30-11). For infection of primary CD4 +T cells (RNA-Seq,
cytokine arrays, qRT-PCR), virus stocks were concentrated 20-fold via ultracentrifugation (96325 g,
120 min, 4˚C, UC OptimaTM L-80 XP Ultracentrifuge (Beckman Coulter, Brea, CA), Swinging-Bucket
Rotor SW Ti-32) and for each of the three HIV-1 strains, wild type and mutant viruses were adjusted
for infectivity using a TZM-bl reporter cell assay.
Infection of TZM-bl reporter cells
6,000 TZM-bl cells were seeded in 96-well plates and infected with 1–100 ml cell culture supernatant
in triplicate on the following day. Three days post-infection, b-galactosidase reporter gene expres-
sion was determined using the GalScreen Kit (Applied Biosystems, Foster City, CA).
Infection of PBMCs and CD4 +T cells
To determine Vpu-mediated effects on tetherin surface levels, 1 million activated PBMCs were
infected with 300 ml non-concentrated VSV-G-pseudotyped HIV-1 for 6 hr in 4 ml tubes before cul-
turing them in 2 ml RPMI-1640 in 6-wells. CD4 +T cells were infected with concentrated virus stocks
via spinoculation (2500 g, 90 min (RNA-Seq) or 1200 g, 120 min (qRT-PCR, cytokine release assays),
37˚C, Centrifuge 5810R (Eppendorf, Hamburg, Germany), Swing-bucket rotor A-4–81).
Flow cytometry
Infection rates and Vpu-mediated tetherin down-modulation in infected primary cells were deter-
mined three days post-infection. To this end, cells were stained extracellularly for tetherin (BioLe-
gend, San Diego, CA, Cat# 348410, dilution 1:20) before fixation, permeabilization (FIX and PERM
Kit, Nordic-MUbio, Susteren, Netherlands) and staining for HIV-1 p24 (Beckman Coulter, Brea, CA,
Cat# 6604665, RRID: AB_1575987, dilution 1:25). Between 1000 and 6000 infected (i.e. p24+) cells
were acquired per sample to monitor tetherin surface expression, whereas 14,000 to 450,000 live
cells were acquired to determine infection rates in Figure 2—figure supplement 1E and Figure 4—
figure supplement 1A,B. To analyze the purity of CD4 +T cells after isolation, cells were simulta-
neously stained for surface CD4 (BD Pharmingen, San Jose, CA, Cat#550631, dilution 1:12.5) and
CD11c (Abcam, Cambridge, UK, Cat# ab22540, dilution 1:5 or #ab82445-100, RRID: AB_1859733,
dilution 1:12.5). In this case, 50,000 to 58,000 live cells were acquired.
Western blotting
To monitor expression of Vpu, transfected HEK293T cells were washed in PBS and lysed in Western
Blot lysis buffer (150 mM NaCl, 50 mM HEPES, 5 mM EDTA, 0.1% NP40, 500 mM Na3VO4, 500 mM
NaF, pH 7.5). Lysates were subsequently mixed with Protein Sample Loading Buffer supplemented
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with 10% b-mercaptoethanol and heated at 95˚C for 5 min. Proteins were separated on NuPAGE 4–
12% Bis-Tris Gels, blotted onto Immobilon-FL PVDF membranes and stained using primary antibod-
ies directed against Vpu (CH293 and STCO1 Vpu: NIH AIDS Reagent Program, #11942, dilution
1:5000; CH077 Vpu: antiserum kindly provided by S. Bolduan, dilution 1:500), p24 (Abcam, #ab9071,
dilution 1:5000), GAPDH (BioLegend, #607902, dilution 1:1000) and Infrared Dye labeled secondary
antibodies (LI-COR IRDye, dilution 1:20000). Signal Enhancer HIKARI kit for Western Blotting and
ELISA (Nacalai Tesque, #02267–41) was used for Vpu and p24 staining. Proteins were detected using
a LI-COR Odyssey scanner.
Virus release assay
To assess Vpu-mediated enhancement of virion release, HEK293T cells were seeded in 6-well plates
and transfected with 5 mg of a proviral construct and increasing amounts of a plasmid coexpressing
human tetherin. 40 hr post-transfection, infectious virus yield was determined by infecting TZM-bl
reporter cells.
NF-kB reporter assay
HEK293T cells were co-transfected with a firefly luciferase reporter construct under the control of
three NF-кB binding sites (200 ng), a Gaussia luciferase construct under the control of a minimal
pTAL promoter for normalization (25 ng), an expression plasmid for a constitutively active mutant of
IKKb (100 ng), and a proviral HIV-1 construct (100 ng). All transfections were performed in 96-well
plates, in triplicates, using the calcium phosphate method. 40 hr post-transfection, firefly and Gaus-
sia luciferase activities were determined using the Luciferase Assay System from Promega and a
homemade assay, respectively. Firefly luciferase signals were normalized to the respective Gaussia
luciferase control.
Immunofluorescence microscopy
HEK293T cells were seeded on Poly-L-Lysine-coated coverslips in 24-well plates and transfected with
a proviral construct or an empty vector (750 ng). Two days post-transfection, cells were stimulated
with 5 ng/ml TNFa for 15 min or left untreated. Subsequently, cells were fixed for 20 min at room
temperature with 4% paraformaldehyde and permeabilized using PBS containing 0.5% Triton
X-100% and 5% FCS for 20 min at room temperature. Proteins were detected using antibodies
against HIV-1 p24 (Abcam, #ab9071, dilution 1:500), p65 (Santa Cruz, #sc-372, dilution 1:150) and
fluorophore-conjugated secondary antibodies (Thermo Scientific #A31571 and #A11011, dilution
1:350). Nuclei were visualized by DAPI staining. Cells were mounted in Mowiol mounting medium
(Cold Spring Harbor Protocols) and analyzed using confocal microscopy (LSM 710, Zeiss) and the
corresponding software (Zeiss Zen Software). The subcellular localization of p65 was quantified using
Fiji. To this end, the average p65 intensity of defined areas (25  25 squares) in the cytoplasm and
nucleus of p24 positive cells was determined in a blinded manner. The p65 intensity in the nucleus
was divided by that of the cytoplasm to determine the nuclear translocation rate of p65. All ratios
were normalized to p65 levels of p24-negative bystander cells to account for possible differences in
staining efficiency between different wells.
Library construction and transcriptome sequencing
Total RNA was isolated and purified from infected CD4 +T cells using the RNeasy Plus Mini Kit (QIA-
GEN, Hilden, Germany). To monitor RNA quality, RNA Integrity Number (RIN) score was analyzed
using an Agilent 2100 Bioanalyzer System (Supplementary file 1) (Schroeder et al., 2006). RNA
sequencing libraries were generated from 150 ng of RNA using Illumina’s TruSeq Stranded mRNA
Sample Prep Kit following manufacturer’s instructions, modifying the shear time to 5 min. RNA librar-
ies were multiplexed and sequenced with 50 base pair (bp) single reads (SR50) to a depth of approx-
imately 30 million reads per sample on an Illumina HiSeq4000.
qRT-PCR
Total RNA was isolated and purified from pelleted CD4 +T cells using the RNeasy Plus Mini Kit (QIA-
GEN, Hilden, Germany). Cells were homogenized by vortexing for 30 s. Subsequent gDNA digestion
was performed using the DNA-free DNA Removal Kit (ThermoFisher Scientific, Waltham, MA). The
Langer et al. eLife 2019;8:e41930. DOI: https://doi.org/10.7554/eLife.41930 18 of 25
Research article Immunology and Inflammation Microbiology and Infectious Disease
maximal amount of RNA was reversely transcribed with the PrimeScript RT Reagent Kit (Perfect Real
Time) (TAKARA, Kusatsu, Japan) using Oligo dT primers and random hexamers. cDNA was sub-
jected to quantitative real time PCR using primer/probe sets for human IFNB1 and GAPDH (Thermo-
Fisher Scientific, Waltham, MA) in singleplex reactions. Samples were analyzed in triplicates. Ct data
were processed relative to the GAPDH control.
Flow-cytometric cytokine quantification
Three days post-infection, cell culture supernatants of infected CD4 +T cells were analyzed using the
LEGENDplex Human Anti-Virus Response Panel, (BioLegend, San Diego, CA, Cat#740390) according
to the manufacturer’s instructions. 5000 events were acquired per sample.
Membrane-based cytokine array
Three days post-infection, cleared cell culture supernatants were analyzed using the RayBio C-Series
Human Cytokine Antibody Array C5 (RayBiotech, Norcross, GA, Cat#AAH-CYT-5–8). The assay was
performed according to the manufacturer’s instructions with the exception that bound antibodies
were labeled with IRDye 800CW labeled streptavidin (LI-COR Biosciences, Lincoln, NE, Cat#926–
32230, dilution 1:1000) for detection via the Odyssey infrared imaging system (LI-COR Biosciences,
Lincoln, NE). Spot intensities were quantified using LI-COR Image Studio Lite Version 3.1.
Quantification and statistical analyses
Cells from four donors were mock infected or infected with three different HIV-1 isolates, each either
wt or one of three vpu mutants (Figure 1B), resulting in a total number of 52 samples subjected to
RNA sequencing and subsequent statistical analysis (Supplementary file 1). The analysis of three dif-
ferent primary HIV-1 isolates in four healthy donors (two women, two men) allowed us to reliably
determine the relative impact of donor, virus and vpu status on host gene expression. Kallisto
(v0.43) was used to build an index using the GRCh38 Homo sapiens reference transcriptome, fol-
lowed by pseudo-alignment of RNA-Seq reads and quantification of transcript abundances
(Bray et al., 2016). All bioinformatic and statistical analyses were performed in R (v3.3.2). Transcript
counts were associated with gene IDs for gene-level summarization. No outliers were detected
based on principal component analysis and considering Cook’s distance (Figure 2B and Figure 2—
figure supplement 1C). Differential expression analyses were performed using the DESeq2 package
(v1.16.1) (Love et al., 2014), which is based on negative binomial generalized linear models. The
GAGE package (v2.22.0) was used for all gene set and pathway analyses. It performs a two-sample
t-test on log fold changes of gene expression levels and derives a global p-value using a meta-test
on the negative log sum of p-values from all one-on-one comparisons (Luo et al., 2009). Statistical
significance for all tests was defined as q < 0.1 after FDR correction. Phenotypic properties of the
HIV-1 clones analyzed in this study (Figure 1C–E and Figure 1—figure supplements 1B and
2B) and their effects on cytokine production (Figure 4) are shown a mean values ± standard error of
the man (SEM). In these experiments, statistical significance was tested using repeated measure
(RM) one-way ANOVA with Greenhouse-Geisser correction and Dunnett’s multiple comparison test
(Figures 1C, D, 4A and C) or ordinary one-way ANOVA and Dunnett’s multiple comparison test
(Figure 1—figure supplements 1B and 2B).
Sequence analyses
Vpu amino acid sequences were aligned using MultAlin (Corpet, 1988) and the Vpu transmembrane
domain was predicted using TMHMM Server v. 2.0 (Krogh et al., 2001).
Availability of data, software, and research materials
The RNA-Seq data have been uploaded to the Gene Expression Omnibus (GEO) database (acces-
sion number #GSE117655).
Acknowledgments
We thank Martha Mayer, Regina Linsenmeyer, Kerstin Regensburger, Susanne Engelhart and Daniela
Krnavek for excellent technical assistance and Konstantin Sparrer for help with confocal imaging
Langer et al. eLife 2019;8:e41930. DOI: https://doi.org/10.7554/eLife.41930 19 of 25
Research article Immunology and Inflammation Microbiology and Infectious Disease
analysis. We also thank Beatrice H. Hahn and Bernd Baumann for providing proviral HIV-1 clones
and NF-kB reporter vectors, respectively. We further thank Birgit Liss and Desiree Spaich for provid-
ing access to the 2100 Bioanalyzer. TZM-bl cells were provided by the NIH AIDS Reagent Program,
Division of AIDS, NIAID, NIH from John C Kappes, Xiaoyun Wu and Tranzyme Inc (Platt et al.,
1998). Vpu-specific antisera were kindly provided by Beatrice H Hahn (via the NIH AIDS Reagent
Program, Division of AIDS, NIAID, NIH) and Sebastian Bolduan. RNA-Seq was conducted at the IGM
Genomics Center, University of California, San Diego, La Jolla, CA. SL, KH, and DH were supported
by the International Graduate School in Molecular Medicine Ulm (IGradU).
Additional information
Funding
Funder Grant reference number Author
International Graduate School
in Molecular Medicine Ulm
Simon Langer
Kristina Hopfensperger
Dominik Hotter
Deutsche Forschungsge-
meinschaft
404687549 Simon Langer
James B. Pendleton Charitable
Trust
Simon Langer
Paul D De Jesus
Kristina M Herbert
Lars Pache
Sumit K Chanda
European Research Council Johannes A van der Merwe
Frank Kirchhoff
Deutsche Forschungsge-
meinschaft
SPP 1923 Frank Kirchhoff
The funders had no role in study design, data collection and interpretation, or the
decision to submit the work for publication.
Author contributions
Simon Langer, Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation,
Writing—review and editing; Christian Hammer, Data curation, Software, Formal analysis, Visualiza-
tion, Methodology, Writing—review and editing; Kristina Hopfensperger, Formal analysis, Validation,
Investigation, Writing—review and editing; Lukas Klein, Formal analysis, Investigation; Dominik Hot-
ter, Resources, Investigation, Methodology, Writing—review and editing; Paul D De Jesus, Lars
Pache, Data curation, Formal analysis; Kristina M Herbert, Data curation, Formal analysis, Methodol-
ogy, Writing—review and editing; Nikaı¨a Smith, Methodology, Writing—review and editing;
Johannes A van der Merwe, Methodology; Sumit K Chanda, Resources, Funding acquisition, Writ-
ing—review and editing; Jacques Fellay, Resources, Software; Frank Kirchhoff, Resources, Supervi-
sion, Funding acquisition, Writing—review and editing; Daniel Sauter, Conceptualization, Resources,
Data curation, Formal analysis, Supervision, Funding acquisition, Visualization, Methodology, Writ-
ing—original draft, Project administration
Author ORCIDs
Christian Hammer http://orcid.org/0000-0003-4548-7548
Nikaı¨a Smith http://orcid.org/0000-0002-0202-612X
Jacques Fellay http://orcid.org/0000-0002-8240-939X
Daniel Sauter http://orcid.org/0000-0001-7665-0040
Ethics
Human subjects: The use of human PBMCs was approved by the Ethics Committee of the Ulm Uni-
versity Medical Center (application #50/16). All donors were anonymized and provided informed
written consent.
Langer et al. eLife 2019;8:e41930. DOI: https://doi.org/10.7554/eLife.41930 20 of 25
Research article Immunology and Inflammation Microbiology and Infectious Disease
Decision letter and Author response
Decision letter https://doi.org/10.7554/eLife.41930.020
Author response https://doi.org/10.7554/eLife.41930.021
Additional files
Supplementary files
. Supplementary file 1. Identity and integrity of RNA-Seq samples.
DOI: https://doi.org/10.7554/eLife.41930.012
. Supplementary file 2. Custom-defined gene set of NF-kB target genes.
DOI: https://doi.org/10.7554/eLife.41930.013
. Supplementary file 3. Custom-defined gene set of host restriction factors.
DOI: https://doi.org/10.7554/eLife.41930.014
. Supplementary file 4. Primers used for mutagenesis of vpu
DOI: https://doi.org/10.7554/eLife.41930.015
. Transparent reporting form
DOI: https://doi.org/10.7554/eLife.41930.016
Data availability
RNA sequencing data have been uploaded to the Gene Expression Omnibus (GEO) database (acces-
sion number GSE117655).
The following dataset was generated:
Author(s) Year Dataset title Dataset URL
Database and
Identifier
Langer S 2018 HIV-1 Vpu exerts broad
immunosuppressive effects by
inhibiting NF-B-dependent gene
expression
https://www.ncbi.nlm.
nih.gov/geo/query/acc.
cgi?acc=GSE117655
NCBI Gene
Expression Omnibus,
GSE117655
References
Abel K, Rocke DM, Chohan B, Fritts L, Miller CJ. 2005. Temporal and anatomic relationship between virus
replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. Journal of
Virology 79:12164–12172. DOI: https://doi.org/10.1128/JVI.79.19.12164-12172.2005, PMID: 16160143
Akari H, Bour S, Kao S, Adachi A, Strebel K. 2001. The human immunodeficiency virus type 1 accessory protein
vpu induces apoptosis by suppressing the nuclear factor kappaB-dependent expression of antiapoptotic
factors. The Journal of Experimental Medicine 194:1299–1312. DOI: https://doi.org/10.1084/jem.194.9.1299,
PMID: 11696595
Apps R, Del Prete GQ, Chatterjee P, Lara A, Brumme ZL, Brockman MA, Neil S, Pickering S, Schneider DK,
Piechocka-Trocha A, Walker BD, Thomas R, Shaw GM, Hahn BH, Keele BF, Lifson JD, Carrington M. 2016. HIV-
1 vpu mediates HLA-C downregulation. Cell Host & Microbe 19:686–695. DOI: https://doi.org/10.1016/j.chom.
2016.04.005, PMID: 27173934
Borges A´H, O’Connor JL, Phillips AN, Ro¨nsholt FF, Pett S, Vjecha MJ, French MA, Lundgren JD, INSIGHT
SMART and ESPRIT Study Groups and the SILCAAT Scientific Committee. 2015. Factors associated with plasma
IL-6 levels during HIV infection. The Journal of Infectious Diseases 212:585–595. DOI: https://doi.org/10.1093/
infdis/jiv123, PMID: 25722296
Bour S, Perrin C, Akari H, Strebel K. 2001. The human immunodeficiency virus type 1 vpu protein inhibits NF-
kappa B activation by interfering with beta TrCP-mediated degradation of ikappa B. Journal of Biological
Chemistry 276:15920–15928. DOI: https://doi.org/10.1074/jbc.M010533200, PMID: 11278695
Bravo Cruz AG, Shisler JL. 2016. Vaccinia virus K1 ankyrin repeat protein inhibits NF-kB activation by preventing
RelA acetylation. The Journal of General Virology 97:2691–2702. DOI: https://doi.org/10.1099/jgv.0.000576,
PMID: 27503790
Bray NL, Pimentel H, Melsted P, Pachter L. 2016. Near-optimal probabilistic RNA-seq quantification. Nature
Biotechnology 34:525–527. DOI: https://doi.org/10.1038/nbt.3519, PMID: 27043002
Calman AF, Busch MP, Vyas GN, McHugh TM, Stites DP, Peterlin BM. 1988. Transcription and replication of
human immunodeficiency virus-1 in B lymphocytes in vitro. AIDS 2:185–193. PMID: 2840098
Chan JK, Greene WC. 2012. Dynamic roles for NF-kB in HTLV-I and HIV-1 retroviral pathogenesis. Immunological
Reviews 246:286–310. DOI: https://doi.org/10.1111/j.1600-065X.2012.01094.x, PMID: 22435562
Langer et al. eLife 2019;8:e41930. DOI: https://doi.org/10.7554/eLife.41930 21 of 25
Research article Immunology and Inflammation Microbiology and Infectious Disease
Chang ST, Sova P, Peng X, Weiss J, Law GL, Palermo RE, Katze MG. 2011. Next-Generation sequencing reveals
HIV-1-Mediated suppression of T cell activation and RNA processing and regulation of noncoding RNA
expression in a CD4+ T cell line. mBio 2. DOI: https://doi.org/10.1128/mBio.00134-11
Chemudupati M, Kenney AD, Bonifati S, Zani A, McMichael TM, Wu L, Yount JS. 2019. From APOBEC to ZAP:
diverse mechanisms used by cellular restriction factors to inhibit virus infections. Biochimica Et Biophysica Acta
(BBA) - Molecular Cell Research 1866:382–394. DOI: https://doi.org/10.1016/j.bbamcr.2018.09.012
Corpet F. 1988. Multiple sequence alignment with hierarchical clustering. Nucleic Acids Research 16:10881–
10890. DOI: https://doi.org/10.1093/nar/16.22.10881, PMID: 2849754
Doehle BP, Chang K, Rustagi A, McNevin J, McElrath MJ, Gale M. 2012. Vpu mediates depletion of interferon
regulatory factor 3 during HIV infection by a lysosome-dependent mechanism. Journal of Virology 86:8367–
8374. DOI: https://doi.org/10.1128/JVI.00423-12, PMID: 22593165
DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, Calos MP. 1987. Analysis of mutation in human cells by
using an Epstein-Barr virus shuttle system. Molecular and Cellular Biology 7:379–387. DOI: https://doi.org/10.
1128/MCB.7.1.379, PMID: 3031469
Elser B, Lohoff M, Kock S, Giaisi M, Kirchhoff S, Krammer PH, Li-Weber M. 2002. IFN-gamma represses IL-4
expression via IRF-1 and IRF-2. Immunity 17:703–712. DOI: https://doi.org/10.1016/S1074-7613(02)00471-5,
PMID: 12479817
Falabella P, Varricchio P, Provost B, Espagne E, Ferrarese R, Grimaldi A, de Eguileor M, Fimiani G, Ursini MV,
Malva C, Drezen JM, Pennacchio F. 2007. Characterization of the IkappaB-like gene family in polydnaviruses
associated with wasps belonging to different braconid subfamilies. Journal of General Virology 88:92–104.
DOI: https://doi.org/10.1099/vir.0.82306-0, PMID: 17170441
Faust TB, Binning JM, Gross JD, Frankel AD. 2017. Making sense of multifunctional proteins: human
immunodeficiency virus type 1 accessory and regulatory proteins and connections to transcription. Annual
Review of Virology 4:241–260. DOI: https://doi.org/10.1146/annurev-virology-101416-041654, PMID: 28961413
Fouchier RA, Meyer BE, Simon JH, Fischer U, Malim MH. 1997. HIV-1 infection of non-dividing cells: evidence
that the amino-terminal basic region of the viral matrix protein is important for gag processing but not for
post-entry nuclear import. The EMBO Journal 16:4531–4539. DOI: https://doi.org/10.1093/emboj/16.15.4531,
PMID: 9303297
Gala˜o RP, Le Tortorec A, Pickering S, Kueck T, Neil SJ. 2012. Innate sensing of HIV-1 assembly by tetherin
induces NFkB-dependent proinflammatory responses. Cell Host & Microbe 12:633–644. DOI: https://doi.org/
10.1016/j.chom.2012.10.007, PMID: 23159053
Galaski J, Ahmad F, Tibroni N, Pujol FM, Mu¨ller B, Schmidt RE, Fackler OT. 2016. Cell surface downregulation of
NK cell ligands by Patient-Derived HIV-1 vpu and nef alleles. JAIDS Journal of Acquired Immune Deficiency
Syndromes 72:1–10. DOI: https://doi.org/10.1097/QAI.0000000000000917, PMID: 26656785
Grandvaux N, Servant MJ, tenOever B, Sen GC, Balachandran S, Barber GN, Lin R, Hiscott J. 2002.
Transcriptional profiling of interferon regulatory factor 3 target genes: direct involvement in the regulation of
interferon-stimulated genes. Journal of Virology 76:5532–5539. DOI: https://doi.org/10.1128/JVI.76.11.5532-
5539.2002, PMID: 11991981
Hamlyn E, Fidler S, Sto¨hr W, Cooper DA, Tambussi G, Schechter M, Miro JM, Mcclure M, Weber J, Babiker A,
Porter K, Investigators ST, SPARTAC Trial Investigators. 2014. Interleukin-6 and D-dimer levels at
seroconversion as predictors of HIV-1 disease progression. AIDS 28:869–874. DOI: https://doi.org/10.1097/
QAD.0000000000000155, PMID: 24300544
Hiscott J, Alper D, Cohen L, Leblanc JF, Sportza L, Wong A, Xanthoudakis S. 1989. Induction of human
interferon gene expression is associated with a nuclear factor that interacts with the NF-kappa B site of the
human immunodeficiency virus enhancer. Journal of Virology 63:2557–2566. PMID: 2542571
Horiuchi M, Itoh A, Pleasure D, Ozato K, Itoh T. 2011. Cooperative contributions of interferon regulatory factor 1
(IRF1) and IRF8 to interferon-g-mediated cytotoxic effects on oligodendroglial progenitor cells. Journal of
Neuroinflammation 8:8:8. DOI: https://doi.org/10.1186/1742-2094-8-8
Hoshino S, Konishi M, Mori M, Shimura M, Nishitani C, Kuroki Y, Koyanagi Y, Kano S, Itabe H, Ishizaka Y. 2010.
HIV-1 vpr induces TLR4/MyD88-mediated IL-6 production and reactivates viral production from latency. Journal
of Leukocyte Biology 87:1133–1143. DOI: https://doi.org/10.1189/jlb.0809547, PMID: 20145198
Hotter D, Kirchhoff F, Sauter D. 2013. HIV-1 vpu does not degrade interferon regulatory factor 3. Journal of
Virology 87:7160–7165. DOI: https://doi.org/10.1128/JVI.00526-13, PMID: 23552418
Hotter D, Krabbe T, Reith E, Gawanbacht A, Rahm N, Ayouba A, Van Driessche B, Van Lint C, Peeters M,
Kirchhoff F, Sauter D. 2017. Primate lentiviruses use at least three alternative strategies to suppress NF-kB-
mediated immune activation. PLOS Pathogens 13:e1006598. DOI: https://doi.org/10.1371/journal.ppat.
1006598, PMID: 28859166
Huang X, Liu X, Meyers K, Liu L, Su B, Wang P, Li Z, Li L, Zhang T, Li N, Chen H, Li H, Wu H. 2016. Cytokine
cascade and networks among MSM HIV seroconverters: implications for early immunotherapy. Scientific
Reports 6:36234. DOI: https://doi.org/10.1038/srep36234, PMID: 27830756
Iyer SS, Bibollet-Ruche F, Sherrill-Mix S, Learn GH, Plenderleith L, Smith AG, Barbian HJ, Russell RM, Gondim
MV, Bahari CY, Shaw CM, Li Y, Decker T, Haynes BF, Shaw GM, Sharp PM, Borrow P, Hahn BH. 2017.
Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness. PNAS 114:E590–E599.
DOI: https://doi.org/10.1073/pnas.1620144114, PMID: 28069935
Jakobsen MR, Bak RO, Andersen A, Berg RK, Jensen SB, Tengchuan J, Jin T, Laustsen A, Hansen K, Ostergaard
L, Fitzgerald KA, Xiao TS, Mikkelsen JG, Mogensen TH, Paludan SR. 2013. IFI16 senses DNA forms of the
Langer et al. eLife 2019;8:e41930. DOI: https://doi.org/10.7554/eLife.41930 22 of 25
Research article Immunology and Inflammation Microbiology and Infectious Disease
lentiviral replication cycle and controls HIV-1 replication. PNAS 110:E4571–E4580. DOI: https://doi.org/10.
1073/pnas.1311669110, PMID: 24154727
Jamieson C, McCaffrey PG, Rao A, Sen R. 1991. Physiologic activation of T cells via the T cell receptor induces
NF-kappa B. J Immunol Baltim Md 1950:416–420.
Jiao Y, Zhang T, Wang R, Zhang H, Huang X, Yin J, Zhang L, Xu X, Wu H. 2012. Plasma IP-10 is associated with
rapid disease progression in early HIV-1 infection. Viral Immunology 25:333–337. DOI: https://doi.org/10.1089/
vim.2012.0011, PMID: 22788418
Joas S, Parrish EH, Gnanadurai CW, Lump E, Stu¨rzel CM, Parrish NF, Learn GH, Sauermann U, Neumann B,
Rensing KM, Fuchs D, Billingsley JM, Bosinger SE, Silvestri G, Apetrei C, Huot N, Garcia-Tellez T, Mu¨ller-
Trutwin M, Hotter D, Sauter D, et al. 2018. Species-specific host factors rather than virus-intrinsic virulence
determine primate lentiviral pathogenicity. Nature Communications 9:1371. DOI: https://doi.org/10.1038/
s41467-018-03762-3, PMID: 29636452
Kleinman CL, Doria M, Orecchini E, Giuliani E, Galardi S, De Jay N, Michienzi A. 2014. HIV-1 infection causes a
down-regulation of genes involved in ribosome biogenesis. PLOS ONE 9:e113908. DOI: https://doi.org/10.
1371/journal.pone.0113908, PMID: 25462981
Kluge SF, Sauter D, Kirchhoff F. 2015. SnapShot: antiviral restriction factors. Cell 163:774–774.e1. DOI: https://
doi.org/10.1016/j.cell.2015.10.019, PMID: 26496613
Kmiec D, Iyer SS, Stu¨rzel CM, Sauter D, Hahn BH, Kirchhoff F. 2016. Vpu-Mediated counteraction of tetherin is a
major determinant of HIV-1 interferon resistance. mBio 7. DOI: https://doi.org/10.1128/mBio.00934-16,
PMID: 27531907
Krapp C, Jønsson K, Jakobsen MR. 2018. STING dependent sensing - Does HIV actually care? Cytokine &
Growth Factor Reviews 40:68–76. DOI: https://doi.org/10.1016/j.cytogfr.2018.03.002, PMID: 29548644
Krogh A, Larsson B, von Heijne G, Sonnhammer EL. 2001. Predicting transmembrane protein topology with a
hidden markov model: application to complete genomes. Journal of Molecular Biology 305:567–580.
DOI: https://doi.org/10.1006/jmbi.2000.4315, PMID: 11152613
Kroismayr R, Baranyi U, Stehlik C, Dorfleutner A, Binder BR, Lipp J. 2004. HERC5, a HECT E3 ubiquitin ligase
tightly regulated in LPS activated endothelial cells. Journal of Cell Science 117:4749–4756. DOI: https://doi.
org/10.1242/jcs.01338, PMID: 15331633
Kuwata T, Gongora C, Kanno Y, Sakaguchi K, Tamura T, Kanno T, Basrur V, Martinez R, Appella E, Golub T,
Ozato K. 2002. Gamma interferon triggers interaction between ICSBP (IRF-8) and TEL, recruiting the histone
deacetylase HDAC3 to the interferon-responsive element. Molecular and Cellular Biology 22:7439–7448.
DOI: https://doi.org/10.1128/MCB.22.21.7439-7448.2002, PMID: 12370291
Leulier F, Marchal C, Miletich I, Limbourg-Bouchon B, Benarous R, Lemaitre B. 2003. Directed expression of the
HIV-1 accessory protein vpu in Drosophila fat-body cells inhibits Toll-dependent immune responses. EMBO
Reports 4:976–981. DOI: https://doi.org/10.1038/sj.embor.embor936, PMID: 12973300
Libermann TA, Baltimore D. 1990. Activation of interleukin-6 gene expression through the NF-kappa B
transcription factor. Molecular and Cellular Biology 10:2327–2334. DOI: https://doi.org/10.1128/MCB.10.5.
2327, PMID: 2183031
Liovat AS, Rey-Cuille´ MA, Le´curoux C, Jacquelin B, Girault I, Petitjean G, Zitoun Y, Venet A, Barre´-Sinoussi F,
Lebon P, Meyer L, Sinet M, Mu¨ller-Trutwin M. 2012. Acute plasma biomarkers of T cell activation set-point
levels and of disease progression in HIV-1 infection. PLOS ONE 7:e46143. DOI: https://doi.org/10.1371/journal.
pone.0046143, PMID: 23056251
Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and dispersion for RNA-seq data with
DESeq2. Genome Biology 15:550. DOI: https://doi.org/10.1186/s13059-014-0550-8, PMID: 25516281
Luo W, Friedman MS, Shedden K, Hankenson KD, Woolf PJ. 2009. GAGE: generally applicable gene set
enrichment for pathway analysis. BMC Bioinformatics 10:161. DOI: https://doi.org/10.1186/1471-2105-10-161,
PMID: 19473525
Manganaro L, de Castro E, Maestre AM, Olivieri K, Garcı´a-Sastre A, Fernandez-Sesma A, Simon V. 2015. HIV vpu
interferes with NF-kB activity but not with interferon regulatory factor 3. Journal of Virology 89:9781–9790.
DOI: https://doi.org/10.1128/JVI.01596-15, PMID: 26178989
Miedema F, Hazenberg MD, Tesselaar K, van Baarle D, de Boer RJ, Borghans JA. 2013. Immune activation and
collateral damage in AIDS pathogenesis. Frontiers in Immunology 4:298. DOI: https://doi.org/10.3389/fimmu.
2013.00298, PMID: 24133492
Noel N, Boufassa F, Le´curoux C, Saez-Cirion A, Bourgeois C, Dunyach-Remy C, Goujard C, Rouzioux C, Meyer L,
Pancino G, Venet A, Lambotte O, ANRS C021 CODEX Study Group. 2014. Elevated IP10 levels are associated
with immune activation and low CD4+ T-cell counts in HIV controller patients. AIDS 28:467–476. DOI: https://
doi.org/10.1097/QAD.0000000000000174, PMID: 24378753
Ochsenbauer C, Edmonds TG, Ding H, Keele BF, Decker J, Salazar MG, Salazar-Gonzalez JF, Shattock R, Haynes
BF, Shaw GM, Hahn BH, Kappes JC. 2012. Generation of transmitted/founder HIV-1 infectious molecular clones
and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages.
Journal of Virology 86:2715–2728. DOI: https://doi.org/10.1128/JVI.06157-11, PMID: 22190722
Ohmori Y, Hamilton TA. 1993. Cooperative interaction between interferon (IFN) stimulus response element and
kappa B sequence motifs controls IFN gamma- and lipopolysaccharide-stimulated transcription from the murine
IP-10 promoter. The Journal of Biological Chemistry 268:6677–6688. PMID: 8454640
Okumura A, Alce T, Lubyova B, Ezelle H, Strebel K, Pitha PM. 2008. HIV-1 accessory proteins VPR and vif
modulate antiviral response by targeting IRF-3 for degradation. Virology 373:85–97. DOI: https://doi.org/10.
1016/j.virol.2007.10.042, PMID: 18082865
Langer et al. eLife 2019;8:e41930. DOI: https://doi.org/10.7554/eLife.41930 23 of 25
Research article Immunology and Inflammation Microbiology and Infectious Disease
Park SY, Waheed AA, Zhang ZR, Freed EO, Bonifacino JS. 2014. HIV-1 vpu accessory protein induces caspase-
mediated cleavage of IRF3 transcription factor. Journal of Biological Chemistry 289:35102–35110. DOI: https://
doi.org/10.1074/jbc.M114.597062, PMID: 25352594
Parrish NF, Gao F, Li H, Giorgi EE, Barbian HJ, Parrish EH, Zajic L, Iyer SS, Decker JM, Kumar A, Hora B, Berg A,
Cai F, Hopper J, Denny TN, Ding H, Ochsenbauer C, Kappes JC, Galimidi RP, West AP, et al. 2013. Phenotypic
properties of transmitted founder HIV-1. PNAS 110:6626–6633. DOI: https://doi.org/10.1073/pnas.
1304288110, PMID: 23542380
Pfeffer LM, Kim JG, Pfeffer SR, Carrigan DJ, Baker DP, Wei L, Homayouni R. 2004. Role of nuclear factor-kappaB
in the antiviral action of interferon and interferon-regulated gene expression. Journal of Biological Chemistry
279:31304–31311. DOI: https://doi.org/10.1074/jbc.M308975200, PMID: 15131130
Pickering S, Hue´ S, Kim EY, Reddy S, Wolinsky SM, Neil SJ. 2014. Preservation of tetherin and CD4 counter-
activities in circulating vpu alleles despite extensive sequence variation within HIV-1 infected individuals. PLOS
Pathogens 10:e1003895. DOI: https://doi.org/10.1371/journal.ppat.1003895, PMID: 24465210
Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. 1998. Effects of CCR5 and CD4 cell surface
concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. Journal of
Virology 72:2855–2864. PMID: 9525605
Ramirez PW, Famiglietti M, Sowrirajan B, DePaula-Silva AB, Rodesch C, Barker E, Bosque A, Planelles V. 2014.
Downmodulation of CCR7 by HIV-1 Vpu results in impaired migration and chemotactic signaling within CD4+ T
cells. Cell Reports 7:2019–2030. DOI: https://doi.org/10.1016/j.celrep.2014.05.015, PMID: 24910430
Revilla Y, Callejo M, Rodrı´guez JM, Culebras E, Nogal ML, Salas ML, Vin˜uela E, Fresno M. 1998. Inhibition of
nuclear factor kappaB activation by a virus-encoded IkappaB-like protein. Journal of Biological Chemistry 273:
5405–5411. DOI: https://doi.org/10.1074/jbc.273.9.5405, PMID: 9479002
Rusinova I, Forster S, Yu S, Kannan A, Masse M, Cumming H, Chapman R, Hertzog PJ. 2013. Interferome v2.0:
an updated database of annotated interferon-regulated genes. Nucleic Acids Research 41:D1040–D1046.
DOI: https://doi.org/10.1093/nar/gks1215, PMID: 23203888
Sauter D, Hotter D, Engelhart S, Giehler F, Kieser A, Kubisch C, Kirchhoff F. 2013. A rare missense variant
abrogates the signaling activity of tetherin/BST-2 without affecting its effect on virus release. Retrovirology 10:
85. DOI: https://doi.org/10.1186/1742-4690-10-85, PMID: 23937976
Sauter D, Hotter D, Van Driessche B, Stu¨rzel CM, Kluge SF, Wildum S, Yu H, Baumann B, Wirth T, Plantier JC,
Leoz M, Hahn BH, Van Lint C, Kirchhoff F. 2015. Differential regulation of NF-kB-mediated proviral and antiviral
host gene expression by primate lentiviral nef and vpu proteins. Cell Reports 10:586–599. DOI: https://doi.org/
10.1016/j.celrep.2014.12.047, PMID: 25620704
Sauter D, Kirchhoff F. 2018. Multilayered and versatile inhibition of cellular antiviral factors by HIV and SIV
accessory proteins. Cytokine & Growth Factor Reviews 40:3–12. DOI: https://doi.org/10.1016/j.cytogfr.2018.
02.005, PMID: 29526437
Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M, Lightfoot S, Menzel W, Granzow M,
Ragg T. 2006. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC
Molecular Biology 7:3. DOI: https://doi.org/10.1186/1471-2199-7-3, PMID: 16448564
Simon V, Bloch N, Landau NR. 2015. Intrinsic host restrictions to HIV-1 and mechanisms of viral escape. Nature
Immunology 16:546–553. DOI: https://doi.org/10.1038/ni.3156, PMID: 25988886
Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, Lebedeva M, DeCamp A, Li D, Grove D, Self SG,
Borrow P. 2009. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human
immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B
and C virus infections. Journal of Virology 83:3719–3733. DOI: https://doi.org/10.1128/JVI.01844-08, PMID: 1
9176632
Tamura T, Thotakura P, Tanaka TS, Ko MS, Ozato K. 2005. Identification of target genes and a unique cis
element regulated by IRF-8 in developing macrophages. Blood 106:1938–1947. DOI: https://doi.org/10.1182/
blood-2005-01-0080, PMID: 15947094
Tokarev A, Suarez M, Kwan W, Fitzpatrick K, Singh R, Guatelli J. 2013. Stimulation of NF-kB activity by the HIV
restriction factor BST2. Journal of Virology 87:2046–2057. DOI: https://doi.org/10.1128/JVI.02272-12,
PMID: 23221546
Vaidya SA, Korner C, Sirignano MN, Amero M, Bazner S, Rychert J, Allen TM, Rosenberg ES, Bosch RJ, Altfeld
M. 2014. Tumor necrosis factor a is associated with viral control and early disease progression in patients with
HIV type 1 infection. The Journal of Infectious Diseases 210:1042–1046. DOI: https://doi.org/10.1093/infdis/
jiu206, PMID: 24688071
Vigan R, Neil SJ. 2010. Determinants of tetherin antagonism in the transmembrane domain of the human
immunodeficiency virus type 1 vpu protein. Journal of Virology 84:12958–12970. DOI: https://doi.org/10.1128/
JVI.01699-10, PMID: 20926557
Xie X, Lu J, Kulbokas EJ, Golub TR, Mootha V, Lindblad-Toh K, Lander ES, Kellis M. 2005. Systematic discovery
of regulatory motifs in human promoters and 3’ UTRs by comparison of several mammals. Nature 434:338–345.
DOI: https://doi.org/10.1038/nature03441, PMID: 15735639
Yamada E, Yoshikawa R, Nakano Y, Misawa N, Koyanagi Y, Sato K. 2015. Impacts of humanized mouse models
on the investigation of HIV-1 infection: illuminating the roles of viral accessory proteins in vivo. Viruses 7:1373–
1390. DOI: https://doi.org/10.3390/v7031373, PMID: 25807049
Yamada E, Nakaoka S, Klein L, Reith E, Langer S, Hopfensperger K, Iwami S, Schreiber G, Kirchhoff F, Koyanagi
Y, Sauter D, Sato K. 2018. Human-Specific adaptations in vpu conferring Anti-tetherin activity are critical for
Langer et al. eLife 2019;8:e41930. DOI: https://doi.org/10.7554/eLife.41930 24 of 25
Research article Immunology and Inflammation Microbiology and Infectious Disease
efficient early HIV-1 replication in Vivo. Cell Host & Microbe 23:110–120. DOI: https://doi.org/10.1016/j.chom.
2017.12.009, PMID: 29324226
Yoh SM, Schneider M, Seifried J, Soonthornvacharin S, Akleh RE, Olivieri KC, De Jesus PD, Ruan C, de Castro E,
Ruiz PA, Germanaud D, des Portes V, Garcı´a-Sastre A, Ko¨nig R, Chanda SK. 2015. PQBP1 is a proximal sensor
of the cGAS-Dependent innate response to HIV-1. Cell 161:1293–1305. DOI: https://doi.org/10.1016/j.cell.
2015.04.050, PMID: 26046437
Langer et al. eLife 2019;8:e41930. DOI: https://doi.org/10.7554/eLife.41930 25 of 25
Research article Immunology and Inflammation Microbiology and Infectious Disease
